Health Economics›Mantle cell lymphoma›First-line therapy

First-line therapy

Mantle cell lymphoma · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cyclophosphamide and Fludarabine (FC) Variant #15	—	R 192 642	—	—	37.0 mo	—	—	1
FCR Variant #09	—	R 70 417	28d	—	44.5 mo	—	—	1
MCP Variant #01	—	R 6 506	28d	—	—	—	—	—
VAD+C Variant #01	—	R 2 356	35d	—	—	—	—	—
CHOP Variant #13	—	R 859	21d	—	—	—	—	1

5 of 5 regimens shown